Filing Details

Accession Number:
0001358403-16-000273
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-23 18:56:18
Reporting Period:
2016-09-21
Filing Date:
2016-09-23
Accepted Time:
2016-09-23 18:56:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358403 Bellicum Pharmaceuticals Inc BLCM Pharmaceutical Preparations (2834) 201450200
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1626808 M. Kevin Slawin C/O Bellicum Pharmaceuticals, Inc.
2130 W. Holcombe Blvd., Ste. 800
Houston TX 77030
Chief Technology Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-09-21 100 $20.04 95,464 No 4 S Direct
Common Stock Disposition 2016-09-21 100 $20.04 366,940 No 4 S Indirect By the Jordana Slawin 2012 Family Trust
Common Stock Disposition 2016-09-23 11,258 $20.12 84,206 No 4 S Direct
Common Stock Disposition 2016-09-23 11,958 $20.11 354,982 No 4 S Indirect By the Jordana Slawin 2012 Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Indirect By the Jordana Slawin 2012 Family Trust
No 4 S Direct
No 4 S Indirect By the Jordana Slawin 2012 Family Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 398,067 Indirect By the Kevin Slawin 2009 Family Trust
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 23, 2016 by the Reporting Person.
  2. The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.